Replimune Group, Inc. (REPL)

US — Healthcare Sector
Peers: PCVX  LRMR  SNDX  MRUS  STRO  CRNX  SRRK  YMAB  STOK 

Automate Your Wheel Strategy on REPL

With Tiblio's Option Bot, you can configure your own wheel strategy including REPL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol REPL
  • Rev/Share 0.0161
  • Book/Share 3.6793
  • PB 1.272
  • Debt/Equity 0.2267
  • CurrentRatio 6.9399
  • ROIC -0.7109

 

  • MktCap 365301359.0
  • FreeCF/Share -2.4898
  • PFCF -1.6032
  • PE -1.5284
  • Debt/Assets 0.1626
  • DivYield 0
  • ROE -0.6934

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade REPL JP Morgan Neutral Underweight -- -- Sept. 19, 2025
Upgrade REPL Cantor Fitzgerald Neutral Overweight -- -- July 30, 2025
Downgrade REPL BMO Capital Markets Outperform Underperform -- $2 July 23, 2025
Downgrade REPL Barclays Overweight Equal Weight -- $3 July 23, 2025
Downgrade REPL H.C. Wainwright Buy Neutral -- -- July 23, 2025
Downgrade REPL Wedbush Outperform Neutral -- $4 July 22, 2025
Downgrade REPL JP Morgan Overweight Neutral -- $9 July 22, 2025
Downgrade REPL Leerink Partners Outperform Market Perform -- $3 July 22, 2025
Downgrade REPL Piper Sandler Overweight Neutral -- $3 July 22, 2025
Initiation REPL Cantor Fitzgerald -- Overweight -- -- June 20, 2025

News

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
REPL
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Negative

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

Read More
image for news REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
REPL
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
REPL
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.

Read More
image for news Investors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
REPL
Published: September 22, 2025 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Read More
image for news FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm
REPL
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

Read More
image for news REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
REPL
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Allegedly, defendants overstated IGNYTE trial prospects despite issues that led the FDA to deem it inadequate, misleading investors and causing losses.

Read More
image for news REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd
Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.
REPL
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Investors can contact the law firm at no cost to learn more about recovering their losses

Read More
image for news Replimune Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 22, 2025 Deadline to file Lead Plaintiff Motion.
BREAKING: Replimune Shares Drop Over 40%; Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud Lawsuit
REPL
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (Nasdaq: REPL) and certain of its executives.

Read More
image for news BREAKING: Replimune Shares Drop Over 40%; Investors Should Contact Block & Leviton By September 22nd To Join Securities Fraud Lawsuit
Replimune Provides Update Following Type A Meeting with FDA
REPL
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with the U.S. Food and Drug Administration (FDA) on September 16th to discuss the complete response letter (CRL) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma.

Read More
image for news Replimune Provides Update Following Type A Meeting with FDA
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REPL
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) and certain of its officers.

Read More
image for news REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
REPL
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline

Read More
image for news Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
REPL
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline

Read More
image for news Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
REPL
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) and certain of its officers.

Read More
image for news REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
REPL
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.

Read More
image for news Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
REPL
Published: September 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
REPL
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.

Read More
image for news REPL 2-WEEK DEADLINE ALERT: Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
REPL
Published: September 08, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
REPL
Published: September 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Read More
image for news REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
REPL
Published: September 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall.

Read More
image for news Replimune (REPL) Faces Investor Lawsuit After FDA Blocks Cancer Drug Approval - Hagens Berman
Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
REPL
Published: September 04, 2025 by: PRNewsWire
Sentiment: Neutral

SAN FRANCISCO , Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives.

Read More
image for news Investor Lawsuit Targets Replimune (REPL) After FDA Deems RP1 Trial Inadequate - Hagens Berman
Shareholders that lost money on Replimune Group, Inc. (REPL) should contact Levi & Korsinsky about pending Class Action - REPL
REPL
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit.

Read More
image for news Shareholders that lost money on Replimune Group, Inc. (REPL) should contact Levi & Korsinsky about pending Class Action - REPL
Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit
REPL
Published: September 02, 2025 by: PRNewsWire
Sentiment: Neutral

RADNOR, Pa. , Sept. 2, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ("Replimune") (NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the "Class Period").

Read More
image for news Class Action Reminder for REPL Investors: Kessler Topaz Meltzer & Check, LLP Reminds Replimune Group, Inc. (REPL) Investors of Securities Fraud Class Action Lawsuit
REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
REPL
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Read More
image for news REPLIMUNE GROUP, INC. (NASDAQ: REPL) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Replimune Group, Inc. Investors of Upcoming Deadline
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
REPL
Published: September 02, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA's rejection of its leading cancer drug, RP1.

Read More
image for news Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
REPL
Published: August 29, 2025 by: PRNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune" …

Read More
image for news Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL
Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
REPL
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA's rejection of its leading cancer drug, RP1. The lawsuit alleges that Replimune misled investors by overstating the drug's trial data and failing to disclose critical regulatory risks.

Read More
image for news Replimune (REPL) Faces Investor Lawsuit Following 77% Stock Crash After FDA Rejects Key Drug - Hagens Berman
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
REPL
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

Read More
image for news ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
REPL
Published: August 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
REPL
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPL
REPL
Published: August 22, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025.

Read More
image for news Shareholders that lost money on Replimune Group, Inc.(REPL) should contact Levi & Korsinsky about pending Class Action - REPL

About Replimune Group, Inc. (REPL)

  • IPO Date 2018-07-20
  • Website https://www.replimune.com
  • Industry Biotechnology
  • CEO Sushil Patel
  • Employees 479

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.